title: Trichomegaly induced by erlotinib.
abstract: Erlotinib (Tarceva, Roche) is a chemotherapeutic agent used in the management of advanced non-small cell lung cancer and other malignancies. We present the case of a patient who developed excessive eyelash growth, called trichomegaly, a rare ocular side effect of this drug.
authors: Department of Ophthalmology, Evangelismos Hospital, Athens, Greece. ommation@yahoo.gr
authors: Rebecca
authors: R
authors: Papadopoulos
authors: Vasiliki
authors: V
authors: Chasapi
authors: Alexandre
authors: A
authors: Bachariou
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000187:drug effects*; D005260:Female; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008207:Lymphatic Metastasis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors